A Phase 3 interventional study of Sitagliptin and Comparator: Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-05-23.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 53rd largest by enrollment of the 197 interventional ones that give a count, is one of 12 that started in 2009, is one of 74 in phase 3, and was the 67th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 78 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 12 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 313 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 71st largest by enrollment of the 170 interventional ones that give a count, is one of 18 that started in 2009, is one of 86 in phase 3, and was the 77th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will examine the safety and efficacy of the addition of sitagliptin (MK-0431) compared to placebo in patients with type 2 diabetes mellitus with inadequate glycemic control who are taking pioglitazone and metformin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sitagliptin 100 mg tablet orally once daily for 26 weeks.
Drug: Sitagliptin · Drug: Pioglitazone · Drug: Metformin · Drug: Glipizide
Placebo to sitagliptin orally once daily for 26 weeks.
Drug: Comparator: Placebo · Drug: Pioglitazone · Drug: Metformin · Drug: Glipizide
Sitagliptin 100 mg tablet orally once daily for 26 weeks.
Also known as: Januvia, MK-0431
Placebo to sitagliptin 100 mg tablet orally once daily for 26 weeks.
Participants taking 30 mg or more pioglitazone oral tablet(s) daily at screening in combination with metformin will enter a 4-week dose-stable period followed by a 2-week single-blind run-in and a 26-week treatment period. Participants taking 4 mg or more rosiglitazone oral tablet(s) daily at screening in combination with metformin were to be switched to a corresponding dose of pioglitazone prior to starting a 4-week dose-stable period. Participants who are taking less than 30 mg/day or no pioglitazone at screening will be titrated to a stable dose of at least 30 mg pioglitazone once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with pioglitazone will be up to 42 weeks.
Also known as: Actos
Participants taking 1500 mg or more metformin oral tablet(s) and at least 30 mg pioglitazone or 4 mg rosiglitazone daily at screening will enter a 4-week dose-stable period followed by a 2-week single-blind placebo run-in, and a 26-week treatment period. Participants who are taking less than 1500 mg/day metformin at screening will be titrated to a stable dose of at least 1500 mg metformin once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with metformin will be up to 42 weeks.
Also known as: Glucophage
Participants not meeting specific glycemic controls during the 26-week treatment period will use glipizide oral tablets as rescue therapy. In countries where glipizide is not available, participants will receive a sulfonylurea marketed in that country.
Also known as: Glucotrol
Change From Baseline in Hemoglobin A1c (A1C) at Week 26
Change from baseline reflects the Week 26 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.
Time frame: Baseline and Week 26
Change From Baseline in 2-Hour Post-Meal Glucose (PMG) at Week 26
Change from baseline reflects the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26
Change from baseline reflects the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
| Milestone | Sitagliptin | Placebo |
|---|---|---|
| Started | 157 | 156 |
| Completed | 149 | 136 |
| Not completed | 8 | 20 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Physician decision | 0 | 3 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 5 |
| Withdrew: Contradiction to study medication | 0 | 2 |
| Withdrew: Excluded medication | 2 | 2 |
| Withdrew: Lab abnormalities | 1 | 1 |
Change from baseline reflects the Week 26 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.
| Percent of glycosylated hemoglobin | Sitagliptin | Placebo |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (A1C) at Week 26 | -1.15 ± 0.93 | -0.40 ± 1.00 |
Change from baseline reflects the Week 26 value minus the baseline value.
| mg/dL | Sitagliptin | Placebo |
|---|---|---|
| Change From Baseline in 2-Hour Post-Meal Glucose (PMG) at Week 26 | -54.4 ± 64.4 | -14.7 ± 59.6 |
Change from baseline reflects the Week 26 value minus the baseline value.
| mg/dL | Sitagliptin | Placebo |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 | -20.3 ± 49.5 | -2.8 ± 41.6 |
Collected over Weeks 0 to 26. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin 100 mg | — | 3/157 (1.9%) | 22/157 (14%) |
| Placebo | — | 6/156 (3.8%) | 20/156 (12.8%) |
| Event | Sitagliptin 100 mg | Placebo |
|---|---|---|
| Cardiac arrestCardiac disorders | 0/157 | 1/156 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 0/157 | 1/156 |
| PeritonitisGastrointestinal disorders | 0/157 | 1/156 |
| AppendicitisInfections and infestations | 0/157 | 1/156 |
| Dengue feverInfections and infestations | 0/157 | 1/156 |
| Cartilage injuryInjury, poisoning and procedural complications | 0/157 | 1/156 |
| Patella fractureInjury, poisoning and procedural complications | 0/157 | 1/156 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/157 | 1/156 |
| Chest discomfortGeneral disorders | 1/157 | 0/156 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/157 | 0/156 |
| Event | Sitagliptin 100 mg | Placebo |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 13/157 | 14/156 |
| HypoglycaemiaMetabolism and nutrition disorders | 10/157 | 7/156 |
| Age, Continuous(years) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Mean | 55.7 ± 8.7 | 56.4 ± 9.4 | 56.1 ± 9.0 |
| Sex: Female, Male(Participants) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Female | 60 | 58 | 118 |
| Male | 97 | 98 | 195 |
| Hemoglobin A1c (A1C)(Percent of gylcosylated hemoglobin) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Mean | 8.8 ± 1.0 | 8.7 ± 1.0 | 8.7 ± 1.0 |
| 2-hour post-meal glucose (PMG)(mg/dL) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Mean | 275.5 ± 66.4 | 266.0 ± 62.4 | 270.8 ± 64.5 |
| Fasting plasma glucose (FPG)(mg/dL) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Mean | 179.3 ± 44.3 | 173.6 ± 38.9 | 176.5 ± 41.7 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Apr 2009 to primary completion in Nov 2010, 18 months.
Results were first posted in Feb 2012, 1 year 2 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin